Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Rhea-AI Summary

Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 3:30 p.m. ET. The management team will engage in one-on-one meetings throughout the virtual conference, which runs from September 14-18, 2020. Phathom focuses on developing novel treatments for gastrointestinal diseases, including a late-stage development drug, vonoprazan, aimed at treating acid-related disorders. Recorded sessions will be available for 60 days post-event.

News Market Reaction – PHAT

+7.00%

1 alert

+7.00% News Effect

On the day this news was published, PHAT gained 7.00%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 3:30 p.m. ET on Tuesday, September 15, 2020.

Company management will also participate in one-on-one meetings during the virtual conference which runs from September 14-18, 2020.

To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.  Recordings will be available for 60 days following the event.

About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.  Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.  For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on LinkedIn at www.linkedin.com/company/phathompharma.

CONTACTS

Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Todd Branning
1-877-742-8466
ir@phathompharma.com

FAQ

When will Phathom Pharmaceuticals participate in the Morgan Stanley Global Healthcare Conference?

Phathom Pharmaceuticals will participate on September 15, 2020, at 3:30 p.m. ET.

What is the focus of Phathom Pharmaceuticals?

Phathom Pharmaceuticals focuses on developing treatments for gastrointestinal diseases.

What is vonoprazan and its significance for Phathom?

Vonoprazan is a novel potassium competitive acid blocker in late-stage development for treating acid-related disorders.

How can I access the Phathom Pharmaceuticals conference webcasts?

You can access live webcasts and recordings through the News & Events section of the Phathom website.

How long will the recordings from the conference be available?

The recordings will be available for 60 days after the event.